Colorado BioScience Association (CBSA) has released its 2024 CBSA Policy + Advocacy Report, which summarizes CBSA’s engagement during the Colorado legislative session, the regulatory processes to implement several key bills passed in prior years, and federal policy engagement in 2023-2024. The report highlights the breadth and depth of CBSA’s leadership as the voice of Colorado’s life sciences ecosystem. As CBSA’s Policy + Advocacy team dives into the 2025 Colorado legislative session, which kicked off on Wednesday, January 8^th, we will continue our collaborations with partners and policymakers focused around CBSA’s Policy Priorities. 

A Letter from Amy Goodman, Colorado BioScience Association Vice President and Counsel for Policy + Advocacy 

Colorado Life Sciences Ecosystem:

Colorado BioScience Association (CBSA) leads Policy + Advocacy efforts to support a collaborative, pro-innovation environment for life sciences in Colorado. We actively engage throughout the legislative process in alignment with our Policy Priorities on bills related to innovation, education and workforce, access and cost, and the regulatory environment. We work in collaboration with partners and policymakers to advance state and federal policies that support the companies in our ecosystem and the patients they serve.

In 2024, the Policy + Advocacy team met with legislators, submitted letters, testified during committee hearings and rulemaking hearings, coordinated the engagement of CBSA members, and built coalitions to support policies that would make a meaningful impact on patients and counter legislation that would make it harder for life sciences companies to advance new technologies and treatments for patients. We also kept CBSA members updated and informed every step of the way about policies that could impact their work.

During the 2024 Colorado legislative session, CBSA reviewed, analyzed, and discussed thirty-three bills. Of those, CBSA supported fifteen bills, opposed two bills, took an “amend” position on eight bills, and monitored eight bills.

CBSA also advocated for the life sciences ecosystem and the patients it serves throughout the regulatory process to implement several key bills passed in prior years, including, most notably, the Prescription Drug Affordability Board (PDAB).

In addition, CBSA worked to promote and champion federal legislation that would advance Colorado’s health innovation ecosystem. CBSA collaborated with leading national organizations that work on behalf of life sciences innovators in Colorado and around the country to advocate for shared policy objectives and ensure elected officials hear the collective voice of Colorado’s ecosystem.

CBSA could not lead this work without our members, Board of Directors, the Policy Committee, and the lobbying team at Colorado Legislative Strategies. Thank you to everyone who dedicates their time to advocate for our life sciences community and educate legislators on the impacts and unintended consequences of policy decisions.

Amy Goodman, JD, MBE
Vice President and Counsel for Policy + Advocacy
Colorado BioScience Association